Post Reply
81-87 of 87
Personnal. I go for it, i oredi (applied) to tikam at at ATM.
Sihuan has an enlarged share capital of 470 million shares. Estimated net eps is $0.0478 for FY2006. The IPO will close at 12.00 noon on 21 Mar. Trading is expected to commence on 23 Mar.
From the estimated net IPO proceeds of approximately $38.0 million to be raised by the Group,
- approximately $12.5 million will be used to continue its R&D activities and expand its product offering;
- approximately $4.0 million will be used to increase its distribution network and marketing activities;
- approximately $12.5 million will be used to increase its production capabilities; and
- approximately $9.0 million will be used for general working capital requirements.
Its primary focus is on the R&D, production and sale of cardiocelebral vascular (CV) drugs, which treat diseases affecting the brain, heart and the body's blood vessels.
Wif the current market.. i doubt this will soar when it starts to trade.. Unlike those previous IPOs when the market is bullish.. Most prob i wont for this..
anyone wishes to predict what will be the opening px on its first day of trading...no carrot for the correct prediction...and no stick if you are wrong....goodluck to those who got the ipo.
It's offering 120m shares at $0.43 each. Of this, 5m will be available for public subscription. The IPO price represents an estimated PER of 9x. Profits grew at a compounded anual rate of 71.6% since '03 to reach an estimated RMB89.9m for last year.
The Chinese drug-maker plans to raise around US$40m by selling new shares in an IPO, a source close to the deal said. The company makes drugs used to treat diseases that affect the brain, heart, or blood vessels supplying blood to these organs. The share sale is equivalent to 25.5% of the company, the source said.
Daiwa Securities SMBC Singapore is the lead manager. The company plans to use the proceeds for R&D, and to increase production. It also plans to expand its business in foreign markets such as the United States, Japan, Korea and Europe.